Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.29% is 32% above its 5-year average of -64.80%, around the middle of its 5-year range (-100.68%–19.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 484.97% below its 12-month average of -7.57%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.29%.
RETURN ON EQUITY (ROE)
-44.29%
RETURN ON EQUITY (ROE) AVG TTM
-7.57%
RETURN ON EQUITY (ROE) AVG 3Y
-44.30%
RETURN ON EQUITY (ROE) AVG 5Y
-64.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-484.97%
CURRENT VS 3Y AVG
+0.04%
CURRENT VS 5Y AVG
+31.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-5.42%
vs the sector median at left
Black Diamond Therapeutics, Inc.
Market Cap
$103.43M
Return on Equity (ROE)
-44.29%
TTM Avg
-7.57%
3Y Avg
-44.30%
5Y Avg
-64.80%
Market Cap
$103.06M
Return on Equity (ROE)
-34.11%
TTM Avg
-78.33%
3Y Avg
-16.94%
5Y Avg
-8.09%
Market Cap
$104.18M
Return on Equity (ROE)
-62.61%
TTM Avg
-420.52%
3Y Avg
-378.99%
5Y Avg
-378.99%
Market Cap
$102.57M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$104.62M
Return on Equity (ROE)
-72.02%
TTM Avg
-67.42%
3Y Avg
-55.49%
5Y Avg
-62.36%
Market Cap
$105.33M
Return on Equity (ROE)
-116.28%
TTM Avg
-71.19%
3Y Avg
-41.66%
5Y Avg
-29.50%
Market Cap
$106.50M
Return on Equity (ROE)
-138.73%
TTM Avg
-151.26%
3Y Avg
-114.36%
5Y Avg
-241.91%
Market Cap
$107.00M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$107.47M
Return on Equity (ROE)
-87.45%
TTM Avg
455.42%
3Y Avg
120.34%
5Y Avg
63.42%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $103.43M | -44.29% | -7.57% | -44.30% | -64.80% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | -34.11% | -78.33% | -16.94% | -8.09% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | -62.61% | -420.52% | -378.99% | -378.99% |
| The Joint Corp. (JYNT)vs › | $102.57M | 23.96% | -4.38% | -11.56% | 6.84% |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.62M | -72.02% | -67.42% | -55.49% | -62.36% |
| Definitive Healthcare Corp. (DH)vs › | $105.33M | -116.28% | -71.19% | -41.66% | -29.50% |
| Vivani Medical, Inc. (VANI)vs › | $106.50M | -138.73% | -151.26% | -114.36% | -241.91% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.00M | -99.67% | -40.73% | 98.81% | 13.93% |
| Immunic, Inc. (IMUX)vs › | $107.47M | -87.45% | 455.42% | 120.34% | 63.42% |
| PolyPid Ltd. (PYPD)vs › | $99.23M | -584.65% | -344.54% | -57.14% | -65.05% |
ROE
-44.3%
ROA
-34.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.29% |
| 2026-03-31 | -41.43% |
| 2025-12-31 | 19.93% |
| 2025-09-30 | 17.04% |
| 2025-06-30 | 10.89% |
| 2025-03-31 | 3.60% |
| 2024-12-31 | -83.66% |
| 2024-09-30 | -75.03% |
| 2024-06-30 | -72.55% |
| 2024-03-31 | -76.50% |
| 2023-12-31 | -70.62% |
| 2023-09-30 | -62.62% |
| 2023-06-30 | -100.68% |
| 2023-03-31 | -88.13% |
| 2022-12-31 | -78.80% |
| 2022-09-30 | -72.02% |
| 2022-06-30 | -71.79% |
| 2022-03-31 | -70.01% |
| 2021-12-31 | -64.11% |
| 2021-09-30 | -55.88% |
| 2021-06-30 | -41.91% |
| 2021-03-31 | -30.42% |
| 2020-12-31 | -21.85% |
| 2020-09-30 | -16.65% |
| 2020-06-30 | -13.37% |
| 2020-03-31 | -12.27% |
| 2019-09-30 | -37.39% |
| 2019-06-30 | -73.28% |
| 2019-03-31 | -24.34% |
